IBD: guideline-based cancer surveillance works

  • Singh K & al.
  • J Crohns Colitis
  • 28 Mar 2019

  • International Clinical Digest
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • This single-center study of patients with longstanding Crohn’s disease (CD) and ulcerative colitis (UC) linked guideline-based surveillance to low incidence of colorectal dysplasia (CRD) and colorectal cancer (CRC).
  • Chromoendoscopy was underused.
  • Authors: 
    • "Meeting current...surveillance recommendations may result in low CRC rates in all IBD patients.”
    • “Surveillance earlier than 8 years in the absence of PSC (primary sclerosing cholangitis) is likely not indicated.”

Why this matters

Study design

  • Single-center retrospective cohort study of UC and colonic CD patients with ≥8 years of disease duration or concomitant PSC (n=680).
  • Outcomes: adherence to surveillance guidelines; incidence of CRC, dysplasia.
  • Funding: McGill CAS Research Support Program; Kimberly Sue McCall Award; Nesbitt-McMaster Award; Pfizer.

Key results

  • Median disease duration, 17 years.
  • UC and colonic CD, respectively:
    • Surveillance adherence: 76%, 66% (PSC: 33%).
    • Chromoendoscopy: 2.4%, 0%.
    • Biopsy adequacy: 54%, 29%.
    • Dysplasia detection: 7%, 3%, mostly low-grade dysplasia (LGD); 3 CRC cases found.
    • CRC incidence/100,000 patient-years: 19.5, 25.1.
    • High-grade dysplasia incidence/100,000 patient-years: 58.5, 37.6.
  • Before 8 years of disease duration in UC and CD:
    • Dysplasia: 19.5, 12.5/100,000 patient-years (PSC, 0).
    • CRC: none.

Limitations

  • Rates not population-based.

Please confirm your acceptance

To gain full access to GPnotebook please confirm:

By submitting here you confirm that you have accepted Terms of Use and Privacy Policy of GPnotebook.

Submit